Entering text into the input field will update the search result below

Array Bio's triplet therapy extends survival in late-stage CRC study

  • Results from a Phase 3 clinical trial, BEACON CRC, evaluating Array BioPharma's (NASDAQ:ARRY) BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) + Eli Lilly's ERBITUX (cetuximab) in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) following one or two prior lines of treatment showed a statistically significant improvement in overall survival (OS). The data were presented at the ESMO World Congress on Gastrointestinal Cancer in Barcelona. 
  • Patients receiving the triplet therapy experienced median OS of 9.0 months compared to 5.4 months for ERBITUX + irinotecan-containing regimens (control arm) (p<0.0001). The objective response rate (ORR) in the triplet therapy group was also superior, 26.1% vs. 1.9% (p<0.0001).
  • Median OS in the BRAFTOVI + MEKTOVI doublet arm was 8.4 months vs. 5.4 months in the control arm (p=0.0003). The ORR was 20.4% vs. 1.9% for control (p<0.0001).
  • The data were first reported in May.
  • Related ticker: Pfizer (NYSE:PFE)

Recommended For You

Related Stocks

SymbolLast Price% Chg
PFE
--
ARRY-OLD
--